Key result
Beta-blockers significantly reduced all-cause mortality compared to control in post-myocardial infarction patients (RR 0.63), although this benefit was not observed when restricted to randomized controlled trials.
Why the study?
Beta-blockers are commonly prescribed after MI, but evidence was based on studies conducted before widespread PCI use.
Do beta-blockers reduce all-cause mortality in post-MI patients in the PCI era?
Meta-Analysis (n=102,794)
Do beta-blockers reduce all-cause mortality in post-MI patients in the PCI era?
Effect estimate: RR 0.63 (95% CI 0.47-0.83)
p-value: p=0.001
In a meta-analysis of post-MI patients in the PCI era, beta-blockers were associated with reduced all-cause mortality, MI, and heart failure, although the mortality benefit was driven by observational data rather than RCTs.
Mortality benefit not seen in RCTs; leaves open routine beta-blocker use post-MI in PCI era.
Background Beta-blockers are commonly prescribed to patients after MI. However, the evidence is based on studies conducted before the widespread use of PCI for treating MI. We conducted this meta-analysis to evaluate beta-blockers’ efficacy post-MI in the modern day and age. Methods We conducted our search using and one clinical trial registry to get RCTs and propensity-matched observational studies comparing the use of beta-blockers after MI to control in post-MI patients. The primary outcome of our analysis was the likelihood of all-cause mortality. Results Our analysis included 3 RCTs and 12 propensity-matched observational studies with a total study population of 102,794. Our results showed a statistically significant decrease in all-cause mortality in the beta-blocker group compared to the non-beta-blocker group (RR 0.63, 95% CI 0.47-0.83; p= 0.001). However, this decrease was not observed when only RCTs were considered (RR 0.91). Beta-blockers were also found to reduce the risk of MI and heart failure with RR of 0.86 (95% CI 0.75-1.00; p=0.05) and 0.84 (95% CI 0.73-0.97; p=0.02), respectively. Conclusion Beta-blockers effectively reduce mortality and decrease the risk of MI and heart failure without a significant increase in adverse effects. Thus, our findings support the contemporary use of beta blockers in post-MI patients. However, more long-term studies need to be done to determine the sustained benefits of beta blockers in the context of evolving cardiac care.
No takes yet. Share an insight, caveat, or question.
Irtaza et al. (2024) conducted a meta-analysis in Myocardial Infarction (n=102,794). Beta-blockers vs. Placebo/Control was evaluated on All-cause mortality (RR 0.63, 95% CI 0.47-0.83, p=0.001). Beta-blockers significantly reduced all-cause mortality compared to control in post-myocardial infarction patients (RR 0.63), although this benefit was not observed when restricted to randomized controlled trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: